aspirin

The combination of Danlou tablets and aspirin significantly improves clinical symptoms in CHD patients with phlegm and blood stasis syndrome, reduces serum sPLA2, LP-PLA2, and ox-LDL levels, and inhibits inflammatory responses, suggesting this combination could provide a beneficial adjunctive therapy for managing CHD in these patients. This study serves as a reference for further research on Danlou tablets' role in CHD.

Upon initiation of high-dose immunoglobulin therapy and aspirin, his fever subsided, and his inflammatory markers and imaging findings normalised...Importantly, IL-17A and tumour necrosis factor-α levels were normal, as elevations in these cytokines have been linked to TAK recurrence. Notably, some cases of LVV following COVID-19 do not respond well to treatment; further research, including case accumulation and cytokine profile analysis, is needed to better predict prognosis.

Comparison of the inhibition of COX-2 and its reversibility by AA520, indomethacin (a time-dependent inhibitor), acetylsalicylic acid (ASA) (an irreversible inhibitor), and ibuprofen (a reversible inhibitor) showed that the compound is acting by forming a tightly bound COX-2 interaction. This inhibitor retains PPARα antagonism at the same concentration range. It has the potential to be effective in treating certain types of cancer, such as hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC), where COX-2 and PPARα are overexpressed.

P2, N=88, Not yet recruiting, Virginia Commonwealth University

The arachidonic acid pathway inhibitor aspirin selectively inhibited the growth of ARID1A-deficient CRC, and aspirin sensitized tumors lacking ARID1A to immunotherapy. Together, these findings suggest that blocking arachidonic acid metabolism can enhance immune responses against tumors by activating CD8+ T cells and inhibiting VM, which synergizes with ICIs to improve treatment of ARID1A-deficient CRC.

P4, N=1200, Not yet recruiting, Kyoto University

P4, N=6504, Not yet recruiting, Asan Medical Center

P1, N=10, Active, not recruiting, USDA, Western Human Nutrition Research Center | Trial completion date: Sep 2024 --> Mar 2025

P4, N=3200, Active, not recruiting, University of Vigo | Recruiting --> Active, not recruiting

P4, N=3150, Not yet recruiting, Odense University Hospital

P4, N=103, Active, not recruiting, NYU Langone Health | Recruiting --> Active, not recruiting

P3, N=114, Completed, Swiss Group for Clinical Cancer Research | Active, not recruiting --> Completed | N=185 --> 114

P=N/A, N=432, Recruiting, Central Hospital, Nancy, France | Trial completion date: Oct 2025 --> Oct 2026

P1, N=100, Recruiting, Spectrum Health - Lakeland | Trial completion date: May 2024 --> Jul 2025 | Trial primary completion date: May 2024 --> Jul 2025

P4, N=5068, Not yet recruiting, University of Aarhus

Notably, co-treatment of cells with GAL and staurosporin, D4476, or acetylsalicylic acid prevented PS externalization whereas only the presence of SB203580 and NSC23766 rescued the cells from GAL-induced hemolysis. Ca2+ nucleation and metabolic collapse mediated by PKC/CK1α/COX/p38/Rac1 drive GAL-induced eryptosis and hemolysis. These novel findings carry ramifications for the clinical prospects of GAL in anticancer therapy.

P1, N=38, Not yet recruiting, Bayer | Trial completion date: Dec 2024 --> Mar 2025 | Initiation date: Nov 2024 --> Feb 2025 | Trial primary completion date: Dec 2024 --> Mar 2025

P=N/A, N=200, Enrolling by invitation, Norwegian University of Science and Technology | Not yet recruiting --> Enrolling by invitation

P=N/A, N=300, Recruiting, Cairo University

Ruxolitinib is a Janus kinase inhibitor that can alleviate pruritus and decrease splenomegaly in patients who are intolerant of or resistant to hydroxyurea. To decrease the risk of thrombosis, all patients with PV should be treated with aspirin and therapeutic phlebotomy to maintain a hematocrit of less than 45%. Cytoreductive therapies, such as hydroxyurea or interferon, are recommended for patients at high risk of thrombosis.

Adjuvant treatment with VD can increase the proportion of regulatory T cells in peripheral blood of individuals with recurrent abortion, regulate metabolic disorder, alleviate immune inflammation, and improve pregnancy outcome.

Molecular docking studies revealed that selected protein targets strongly interact with bioactive compounds, and the estimated inhibition constants (Ki) of JAK2, STAT3, COX-2, HPV31 E6, EGFR1, TP53, and PARP1 were significantly decreased compared to acetylsalicylic acid. This could be a clear indication that these protein targets are implicated with antiproliferative efficacy, thereby warranting the potential of (1) and (7) to be used as anti-breast cancer drug candidates.

SANT of the spleen is generally considered a rare, benign lesion with angioma-like characteristics. It exhibits exhibiting distinctive histomorphological features within the red pulp. Understanding the differential diagnosis is crucial to prevent missed or incorrect diagnoses.

P3, N=1184, Recruiting, Capital Medical University | Not yet recruiting --> Recruiting

P4, N=1050, Not yet recruiting, Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University

P2, N=150, Completed, Peter MacCallum Cancer Centre, Australia | Unknown status --> Completed

P3, N=21, Completed, PharmaEssentia Japan K.K. | Recruiting --> Completed

P=N/A, N=1200, Active, not recruiting, Washington University School of Medicine | Not yet recruiting --> Active, not recruiting | N=400 --> 1200 | Trial completion date: Jun 2024 --> Nov 2024

Thus, this pilot study suggests that the reduction in p87 in the right colon is possibly correlated with JAK3 mutations. If confirmed, JAK3 mutations, known to be associated with immune aberrations, may provide a mechanistic explanation for the lack of a p87 (protein 87 kilodaltons) field in some patients with HGD polyps who might benefit from possible intervention such as more intensive screening. Limited microbiome studies were also performed on two patients with familial cancer syndromes and these compared favorably with controls available from the literature.

P4, N=10742, Recruiting, Ohio State University | Not yet recruiting --> Recruiting

P4, N=70, Not yet recruiting, PharmaEssentia | N=110 --> 70 | Trial completion date: Feb 2027 --> Jun 2026 | Initiation date: Jul 2024 --> Jan 2025

P3, N=700, Recruiting, Weill Medical College of Cornell University | Not yet recruiting --> Recruiting

P3, N=400, Active, not recruiting, Weill Medical College of Cornell University | Enrolling by invitation --> Active, not recruiting | Trial completion date: Aug 2024 --> Nov 2024 | Trial primary completion date: Aug 2024 --> Nov 2024

P3, N=1184, Not yet recruiting, Capital Medical University | Initiation date: Aug 2024 --> Nov 2024

P4, N=44, Active, not recruiting, Lawson Health Research Institute | Recruiting --> Active, not recruiting | Trial completion date: Apr 2025 --> Jul 2026 | Trial primary completion date: Feb 2025 --> Feb 2026

P1/2, N=32, Not yet recruiting, University of Aarhus

P1, N=38, Not yet recruiting, Bayer

P4, N=128, Recruiting, Columbia University

P3, N=3200, Recruiting, Children's Hospital of Fudan University | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Dec 2024

P2/3, N=100, Not yet recruiting, Mazandaran University of Medical Sciences

In this study, we found that all of the hub genes are linked with the 10 drug components, and it was observed that aspirin CTD 00005447 was mostly associated with all the other hub genes. This bio-informatics study may help researchers better understand the cause of PTB and its relationship with NCDs, and eventually, this can lead to exploring effective treatment plans.

PV patients with high risk can benefit from low-dose aspirin...Patients with polycythemia vera can present with a high or low serum EPO level. Further diagnostic tests are usually required to confirm the final diagnosis.